<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1507">
  <stage>Registered</stage>
  <submitdate>21/03/2007</submitdate>
  <approvaldate>21/03/2007</approvaldate>
  <nctid>NCT00451711</nctid>
  <trial_identification>
    <studytitle>Intermittent Liposomal Amphotericin B Primary Prophylaxis</studytitle>
    <scientifictitle>A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome® in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IN-AU-131-0176</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myeloid Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Liposomal amphotericin B

Treatment: drugs: Liposomal amphotericin B


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as defined by the incidence of all adverse events occurring by the completion of each trial prophylaxis course.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety:</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of renal toxicity</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of hepatotoxicity</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of ionic abnormalitities</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of cardiovascular toxicity</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy:</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of proven or probable IFI</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of superficial fungal infections</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of fever of unknown origin requiring empirical antifungal therapy during any course of prophylaxis</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of IFI-related mortality</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients fulfilling all the following criteria will be eligible:

          -  Male or female aged &gt;18years;

          -  Newly diagnosed with acute myeloid leukaemia and undergoing first induction
             chemotherapy regimen;

          -  Expected to have absolute neutrophil counts of &lt;0.5x109/L for at least 2 weeks;

          -  Normal high resolution chest and sinus CT scan at baseline;

          -  No signs or symptoms of invasive fungal infections

          -  No prior diagnosis of proven or probable invasive fungal infection within the last 6
             months;

          -  Females of childbearing potential must be: surgically incapable of pregnancy; or
             practicing an acceptable mode of birth control and have a negative pregnancy test
             (blood or urine) at baseline;

          -  Give written informed consent prior to any study-specific procedures;

          -  Must have the ability and must agree to comply with all study requirements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with any of the following will be ineligible

          -  Known hypersensitivity to amphotericin B, in particular known history of anaphylactic
             reaction to amphotericin B;

          -  Patients undergoing any transplantation;

          -  Creatinine clearance &lt;60mL/min/1.72 m2;

          -  Patients with moderate or severe liver disease as defined by aspartate
             aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 5 times the upper limit of
             normal (ULN)

          -  Patients who are unlikely to survive more than one month;

          -  Patients who have received systemic antifungal therapy within the last 15 days

          -  Any severe cardiovascular disease ( in particular arrhythmias) which may constitute a
             contra-indication to LAB (AmBisome®) administration;

          -  Any severe diseases other than acute myeloid leukaemia which in the investigator's
             judgement may interfere with study evaluations or affect the patients safety;

          -  Pregnant or nursing females;

          -  Patients previously included in this study;

          -  Patients who have taken an investigational drug in the last 30 days prior to the
             inclusion.

          -  Patients enrolled in a pre-emptive treatment strategy trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hosptial - Melbourne</hospital>
    <hospital>Box Hill Hospital, Eastern Health - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3129 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Gilead Sciences</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when
      used as a preventer against invasive fungal infection in patients with acute leukaemia who
      are undergoing chemotherapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00451711</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>C. Orla Morrissey, MB, BCh, FRACP</name>
      <address>The Alfred Hospital, Level 2 Burnet Institute, Commercial Rd., Melbourne, 3004, Victoria, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>C. Orla Morrissey, MB, BCh, FRACP</name>
      <address />
      <phone>+61 3 9076 2000</phone>
      <fax />
      <email>o.morrissey@alfred.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>